EP2753641A4 - Peptides de pénétration cellulaire neuroprotecteurs - Google Patents

Peptides de pénétration cellulaire neuroprotecteurs

Info

Publication number
EP2753641A4
EP2753641A4 EP12830062.1A EP12830062A EP2753641A4 EP 2753641 A4 EP2753641 A4 EP 2753641A4 EP 12830062 A EP12830062 A EP 12830062A EP 2753641 A4 EP2753641 A4 EP 2753641A4
Authority
EP
European Patent Office
Prior art keywords
penetrating peptides
neuroprotective cell
neuroprotective
cell
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12830062.1A
Other languages
German (de)
English (en)
Other versions
EP2753641A1 (fr
Inventor
Urmas Arumäe
Mart Saarma
Pia Runeberg-Roos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2753641A1 publication Critical patent/EP2753641A1/fr
Publication of EP2753641A4 publication Critical patent/EP2753641A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP12830062.1A 2011-09-05 2012-09-05 Peptides de pénétration cellulaire neuroprotecteurs Withdrawn EP2753641A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20115870A FI20115870A0 (fi) 2011-09-05 2011-09-05 Neuroprotektiiviset soluihin tunkeutuvat peptidit
PCT/FI2012/050859 WO2013034805A1 (fr) 2011-09-05 2012-09-05 Peptides de pénétration cellulaire neuroprotecteurs

Publications (2)

Publication Number Publication Date
EP2753641A1 EP2753641A1 (fr) 2014-07-16
EP2753641A4 true EP2753641A4 (fr) 2015-06-24

Family

ID=44718780

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12830062.1A Withdrawn EP2753641A4 (fr) 2011-09-05 2012-09-05 Peptides de pénétration cellulaire neuroprotecteurs

Country Status (3)

Country Link
EP (1) EP2753641A4 (fr)
FI (1) FI20115870A0 (fr)
WO (1) WO2013034805A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201491411A1 (ru) 2012-01-24 2014-12-30 Юниверсити Оф Массачусетс Растворимый manf при поражениях бета-клеток поджелудочной железы
WO2014191630A2 (fr) * 2013-05-28 2014-12-04 Helsingin Yliopisto Modèle animal non humain codant pour un gène manf non fonctionnel
EP3113788A4 (fr) 2014-03-05 2017-10-18 Lawrence M. Schwartz Procédés et compositions de protection des cellules sensorielles
EP3122370A1 (fr) * 2014-03-28 2017-02-01 Buck Institute for Research on Aging Méthodes et compositions pour moduler le système immunitaire
WO2015200469A1 (fr) * 2014-06-24 2015-12-30 University Of Massachusetts Manf en tant que régulateur du fonctionnement du système immunitaire
EP3377089B1 (fr) 2015-11-18 2020-04-08 Herantis Pharma Plc Compositions comprenant du cdnf pour le traitement par voie intranasale de maladies du système nerveux central
EP3619227A1 (fr) * 2017-05-04 2020-03-11 Helsingin Yliopisto Fragments cdnf et manf c-terminaux, compositions pharmaceutiques les comprenant et leurs utilisations
EP3774858A1 (fr) * 2018-03-29 2021-02-17 Helsingin Yliopisto Fragments cdnf c-terminaux, compositions pharmaceutiques les comprenant et leurs utilisations
EP3838912A1 (fr) * 2019-12-20 2021-06-23 Herantis Pharma Oyj Peptides rétro inverses
EP3838345A1 (fr) 2019-12-20 2021-06-23 Herantis Pharma Oyj Peptides macrocycliques

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043693A1 (fr) * 1998-02-26 1999-09-02 Human Genome Sciences, Inc. Proteines secretees par l'homme
WO2002074956A2 (fr) * 2001-03-20 2002-09-26 Prescient Neuropharma Inc. Facteurs promoteurs de la survie des neurones dopaminergiques et utilisations associes
WO2002079246A2 (fr) * 2001-03-30 2002-10-10 Geneprot, Inc. Compositions proteiques humaines riches en arginine-
US20030109457A1 (en) * 2001-10-25 2003-06-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress
US20030109690A1 (en) * 1999-09-29 2003-06-12 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
WO2004050688A1 (fr) * 2002-12-02 2004-06-17 Xenome Ltd Nouveaux peptides de $g(x)-conotoxine (-ii)
WO2009133247A1 (fr) * 2008-04-30 2009-11-05 Licentia Oy Facteur neurotrophique manf et ses utilisations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2352205T3 (es) * 2005-12-14 2011-02-16 Licentia Ltd. Usos de una proteína del factor neurotrófico.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043693A1 (fr) * 1998-02-26 1999-09-02 Human Genome Sciences, Inc. Proteines secretees par l'homme
US20030109690A1 (en) * 1999-09-29 2003-06-12 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
WO2002074956A2 (fr) * 2001-03-20 2002-09-26 Prescient Neuropharma Inc. Facteurs promoteurs de la survie des neurones dopaminergiques et utilisations associes
WO2002079246A2 (fr) * 2001-03-30 2002-10-10 Geneprot, Inc. Compositions proteiques humaines riches en arginine-
US20030109457A1 (en) * 2001-10-25 2003-06-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress
WO2004050688A1 (fr) * 2002-12-02 2004-06-17 Xenome Ltd Nouveaux peptides de $g(x)-conotoxine (-ii)
WO2009133247A1 (fr) * 2008-04-30 2009-11-05 Licentia Oy Facteur neurotrophique manf et ses utilisations

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 12 June 2003 (2003-06-12), Database accession no. 536071-66-6 *
JORDAN M. FLETCHER ET AL: "Novel monocyclic and bicyclic loop mimetics of brain-derived neurotrophic factor", JOURNAL OF PEPTIDE SCIENCE, vol. 12, no. 8, 1 January 2006 (2006-01-01), pages 515 - 524, XP055145298, ISSN: 1075-2617, DOI: 10.1002/psc.760 *
M. HELLMAN: "Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) Has a Unique Mechanism to Rescue Apoptotic Neurons", J. BIOL. CHEM., vol. 286, no. 4, 1 January 2011 (2011-01-01), pages 2675 - 2680, XP055145300 *
PÄIVI LINDHOLM ET AL: "Novel CDNF/MANF family of neurotrophic factors", DEVELOPMENTAL NEUROBIOLOGY, 1 January 2010 (2010-01-01), pages NA - NA, XP055145301, ISSN: 1932-8451, DOI: 10.1002/dneu.20760 *
See also references of WO2013034805A1 *
VICTOR J. HRUBY: "Designing peptide receptor agonists and antagonists", NATURE REVIEWS DRUG DISCOVERY, vol. 1, no. 11, 1 November 2002 (2002-11-01), pages 847 - 858, XP055034286, ISSN: 1474-1776, DOI: 10.1038/nrd939 *

Also Published As

Publication number Publication date
FI20115870A0 (fi) 2011-09-05
EP2753641A1 (fr) 2014-07-16
WO2013034805A1 (fr) 2013-03-14

Similar Documents

Publication Publication Date Title
HK1243427A1 (zh) 治療肽
IL233280B (en) Cell-penetrating peptides
SG10201601840RA (en) P53 activating peptides
EP2857033A4 (fr) Peptide à perméation cutanée
EP2753641A4 (fr) Peptides de pénétration cellulaire neuroprotecteurs
GB201012651D0 (en) Peptides
ZA201307169B (en) Neuroprotective peptides
EP2812347A4 (fr) Peptide induisant une autophagie
GB201111183D0 (en) Peptide
GB201115910D0 (en) Peptides
HK1209138A1 (en) Peptides
EP2793918A4 (fr) Peptides de liaison à hdc-sign
EP2627674A4 (fr) Peptides basés sur l'egfr
GB201200555D0 (en) Peptide
GB201204868D0 (en) Peptides
HK1187628A1 (zh) 新型肽
EP2714717A4 (fr) Peptides de phoenixin
PT2891663T (pt) Péptidos derivados de psf1
IL228354A0 (en) Neuroprotective peptides
GB201115014D0 (en) Peptides
GB201220328D0 (en) Peptides
GB201211740D0 (en) Peptides
AU2011903086A0 (en) Peptides
GB201207895D0 (en) Peptides
GB201200509D0 (en) Peptides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140317

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150526

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20150519BHEP

Ipc: A61K 38/18 20060101ALI20150519BHEP

Ipc: C07K 14/475 20060101AFI20150519BHEP

Ipc: A61P 5/00 20060101ALI20150519BHEP

Ipc: A61P 25/00 20060101ALI20150519BHEP

Ipc: A61P 25/30 20060101ALI20150519BHEP

Ipc: C07K 5/103 20060101ALI20150519BHEP

Ipc: A61P 25/16 20060101ALI20150519BHEP

Ipc: A61K 38/07 20060101ALI20150519BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151223